Drug Discovery
By
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
